You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
傳奇生物(LEGN.US)一季度營收同比大增158.6%,手握現金13億美元
格隆匯 05-13 22:25

格隆匯5月13日丨傳奇生物(LEGN.US)公佈2024年第一季度業績。報吿期內,公司營收為9399萬美元,同比增長158.6%,淨虧損大幅收窄。截至2024年3月31日,現金和現金等價物、定期存款和短期投資為13億美元。傳奇生物認為,這些資金將為公司提供到2026年的財務支持,屆時公司預計將實現營業利潤。

2024年第一季度,許可收入為1220萬美元,包括確認與諾華製藥公司簽訂的全球許可協議相關的遞延收入,該協議旨在開發、製造和商業化LB2102和其他選擇性靶向的潛在CAR-T療法DLL3。並未確認2023年第一季度的任何許可收入。2024年第一季度的合作收入為7850萬美元,而2023年第一季度為3630萬美元。這一增長主要是由於與楊森協議相關的CARVYKTI®銷售收入增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account